Suchergebnisse - "Vernaci, Grazia"

PubPharm (23)

1

Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Bottosso, M. | Miglietta, F. | Vernaci, G. | +4

2

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

enthalten in: The oncologist | 2023

von Vernaci, G. | Savarino, E. | Patuzzi, I. | +13

3

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases

enthalten in: British journal of cancer | 2023

von Bottosso, M. | Griguolo, G. | Sinoquet, L. | +10

4

Oligometastatic breast cancer : Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

enthalten in: Cancer treatment reviews | 2022

von Miglietta, F. | Visani, L. | Marini, S. | +6

5

HER2-low-positive breast cancer : evolution from primary tumor to residual disease after neoadjuvant treatment

enthalten in: NPJ breast cancer | 2022

von Miglietta, F. | Griguolo, G. | Bottosso, M. | +12

6

Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer : Available evidence and clinical implications

enthalten in: Cancer treatment reviews | 2022

von Griguolo, G. | Bottosso, M. | Vernaci, G. | +3

7

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer : Results of the Phase II GIADA Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Dieci, M. | Guarneri, V. | Tosi, A. | +15

CommentOn: Clin Cancer Res. 2022 Jan 15;28(2):247. - PMID 35045957

8

Author Correction : Evolution of HER2-low expression from primary to recurrent breast cancer

enthalten in: NPJ breast cancer | 2021

von Miglietta, F. | Griguolo, G. | Bottosso, M. | +11

ErratumFor: NPJ Breast Cancer. 2021 Oct 12;7(1):137. - PMID 34642348

9

Evolution of HER2-low expression from primary to recurrent breast cancer

enthalten in: NPJ breast cancer | 2021

von Miglietta, F. | Griguolo, G. | Bottosso, M. | +11

ErratumIn: NPJ Breast Cancer. 2021 Nov 24;7(1):149. - PMID 34819500

10

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

enthalten in: NPJ breast cancer | 2021

von Dieci, M. | Griguolo, G. | Bottosso, M. | +12